Patents by Inventor Jeffrey S. Stults
Jeffrey S. Stults has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10464912Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: March 3, 2017Date of Patent: November 5, 2019Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
-
Publication number: 20170174643Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z.2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: ApplicationFiled: March 3, 2017Publication date: June 22, 2017Inventors: Isabel KALOFONOS, G. Patrick STAHLY, William MARTIN-DOYLE, Dimitris KALOFONOS, Travis L. HOUSTON, Jeffrey S. STULTS
-
Patent number: 9611234Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: November 4, 2014Date of Patent: April 4, 2017Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Travis L. Houston, Jeffrey S. Stults
-
Patent number: 9546183Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: January 14, 2016Date of Patent: January 17, 2017Assignee: Salix Pharmaceuticals, LtdInventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 9447056Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: GrantFiled: April 11, 2014Date of Patent: September 20, 2016Assignee: BIONEVIA PHARMACEUTICALS, INC.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20160200738Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: January 14, 2016Publication date: July 14, 2016Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 9273066Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: October 24, 2013Date of Patent: March 1, 2016Assignee: Salix Pharmaceuticals, Inc.Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 9034892Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: June 27, 2013Date of Patent: May 19, 2015Assignee: Salix Pharmaceuticals, Inc.Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Publication number: 20150057319Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: ApplicationFiled: November 4, 2014Publication date: February 26, 2015Inventors: Isabel KALOFONOS, Patrick G. STAHLY, William Martin-Doyle, Dimitris KALOFONOS, Travis L. Houston, Jeffrey S. STULTS
-
Patent number: 8906948Abstract: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, treating and/or preventing homocystinuria reducing levels of homocysteine in blood serum, inhibiting aldose reductase, and affording cardioprotection in non-diabetic patients.Type: GrantFiled: September 3, 2009Date of Patent: December 9, 2014Assignee: Bionevia, LLCInventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20140221438Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: ApplicationFiled: April 11, 2014Publication date: August 7, 2014Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20140179916Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: October 24, 2013Publication date: June 26, 2014Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 8754098Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: August 23, 2012Date of Patent: June 17, 2014Assignee: Salix Pharmaceuticals, Ltd.Inventors: Karen S. Gushurst, Donglai Yang, Melanie Janelle Bevill, Nathan Carl Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20140141081Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: June 27, 2013Publication date: May 22, 2014Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 8697735Abstract: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts and cocrystal and the therapeutic use of the novel crystalline salts and cocrystal to treat and/or prevent various conditions, including treating and/or preventing diabetic complications, inhibiting aldose reductase, and affording cardioprotection in patients who may be non-diabetic.Type: GrantFiled: January 25, 2011Date of Patent: April 15, 2014Assignee: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Travis L. Houston
-
Patent number: 8569326Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: August 16, 2012Date of Patent: October 29, 2013Assignee: Salix Pharmaceuticals, Ltd.Inventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Patent number: 8486956Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: GrantFiled: February 19, 2010Date of Patent: July 16, 2013Assignee: Salix Pharmaceuticals, LtdInventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Publication number: 20130066079Abstract: The present invention relates to Rifaximin polymorphic, salt, hydrate, and amorphous forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: August 23, 2012Publication date: March 14, 2013Applicant: Salix Pharmaceuticals, Ltd.Inventors: Karen S. Gushurst, Donglai Yang, Melanie Roe, Nathan Schultheiss, Petinka Vlahova, Jeffrey S. Stults, Travis L. Houston
-
Publication number: 20120316334Abstract: The present invention relates to Rifaximin polymorphic forms, to their use in medicinal preparations and to therapeutic methods using them.Type: ApplicationFiled: August 16, 2012Publication date: December 13, 2012Applicant: SALIX PHARMACEUTICALS, LTDInventors: Karen S. Gushurst, Donglai Yang, Petinka Vlahova, Jeffrey S. Stults
-
Publication number: 20120196895Abstract: The invention relates to novel crystalline forms of (2RS)-1-(4-ethylphenyl)-2-methyl-3-piperidin-1-yl-propan-1-one. The preparation and characterization of the novel crystalline forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline forms, which are useful to treat and/or prevent various conditions such as pathological muscle contracture, myotonic conditions, and spastic paralysis or spasticity caused by various neurologic conditions, and are also useful for the treatment and/or prevention of various types of pain and pathological muscle tension.Type: ApplicationFiled: January 11, 2010Publication date: August 2, 2012Applicant: Bionevia Pharmaceuticals, Inc.Inventors: Isabel Kalofonos, G. Patrick Stahly, William Martin-Doyle, Dimitris Kalofonos, Jeffrey S. Stults, Jason A. Hanko